[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
复制标题
DOI：
10.1007/s00259-016-3498-y
复制
发表时间：
2017-01
影响因子：
9.1
通讯作者：
Dingemans, Anne-Marie C.
中科院分区：
文献类型：
--
作者：
de Jong, Evelyn E. C.;van Elmpt, Wouter;Leijenaar, Ralph T. H.;Hoekstra, Otto S.;Groen, Harry J. M.;Smit, Egbert F.;Boellaard, Ronald;van der Noort, Vincent;Troost, Esther G. C.;Lambin, Philippe;Dingemans, Anne-Marie C.
硝酸甘油（NTG）是一种血管扩张药物，可增加肿瘤血流量，从而减少缺氧。因此，[18 F]氟脱氧葡萄糖正电子发射断层扫描（[18 F]FDG PET）摄取模式可能发生变化。在这项分析中，我们研究了[18 F]FDG PET用于评估紫杉醇-卡铂-贝伐单抗（PCB）治疗（有或无NTG贴片）的反应的可行性。我们将[18F]FDG PET反应评估与RECIST反应评估和生存率进行了比较。一项II期研究（NCT 01171170）共纳入了223名IV期非小细胞肺癌（NSCLC）患者，随机分配使用或不使用NTG贴片的PCB治疗。对于60名参与患者，可获得基线和第二次[18F]FDG PET/计算机断层扫描（CT）扫描，在治疗开始后第22天和第24天之间进行。肿瘤缓解定义为CT和PET参数降低30%，并与第6周的RECIST缓解进行比较。评估了这些评估对无进展生存期（PFS）和总生存期（OS）的预测价值，包括使用和不使用NTG。与CT直径评估降低30%相比，SUV峰值评估降低30%将更多患者确定为应答者（73% vs. 18%），然而，这与OS无关（SUV峰值30 p = 0.833; CT直径30 p = 0.557）。与对照组相比，NTG组基线和第二次扫描之间的PET参数变化无显著差异（p值范围为0.159-0.634）。与对照组相比，NTG组基于CT（[18 F]FDG PET/CT的一部分）的参数显示基线和第二次扫描之间存在显著差异（CT直径分别降低7 ± 23%和19 ± 14%，p = 0.016）。在接受化疗联合或不联合NTG治疗的晚期NSCLC患者中，肿瘤FDG摄取的降低在两个治疗组之间没有差异。早期基于PET的缓解评估显示肿瘤缓解者多于基于CT的缓解评估（[18 F]FDG PET/CT的一部分）;这与生存期无关。这可能是由于[18F]FDG PET的时间安排在贝伐珠单抗输注后不久。
Nitroglycerin (NTG) is a vasodilating drug, which increases tumor blood flow and consequently decreases hypoxia. Therefore, changes in [18F] fluorodeoxyglucose positron emission tomography ([18F]FDG PET) uptake pattern may occur. In this analysis, we investigated the feasibility of [18F]FDG PET for response assessment to paclitaxel-carboplatin-bevacizumab (PCB) treatment with and without NTG patches. And we compared the [18F]FDG PET response assessment to RECIST response assessment and survival. A total of 223 stage IV non-small cell lung cancer (NSCLC) patients were included in a phase II study (NCT01171170) randomizing between PCB treatment with or without NTG patches. For 60 participating patients, a baseline and a second [18F]FDG PET/computed tomography (CT) scan, performed between day 22 and 24 after the start of treatment, were available. Tumor response was defined as a 30 % decrease in CT and PET parameters, and was compared to RECIST response at week 6. The predictive value of these assessments for progression free survival (PFS) and overall survival (OS) was assessed with and without NTG. A 30 % decrease in SUVpeak assessment identified more patients as responders compared to a 30 % decrease in CT diameter assessment (73 % vs. 18 %), however, this was not correlated to OS (SUVpeak30 p = 0.833; CTdiameter30 p = 0.557). Changes in PET parameters between the baseline and the second scan were not significantly different for the NTG group compared to the control group (p value range 0.159–0.634). The CT-based (part of the [18F]FDG PET/CT) parameters showed a significant difference between the baseline and the second scan for the NTG group compared to the control group (CT diameter decrease of 7 ± 23 % vs. 19 ± 14 %, p = 0.016, respectively). The decrease in tumoral FDG uptake in advanced NSCLC patients treated with chemotherapy with and without NTG did not differ between both treatment arms. Early PET-based response assessment showed more tumor responders than CT-based response assessment (part of the [18F]FDG PET/CT); this was not correlated to survival. This might be due to timing of the [18F]FDG PET shortly after the bevacizumab infusion.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
3.7
作者：
Hachemi M;Couturier O;Vervueren L;Fosse P;Lacœuille F;Urban T;Hureaux J
通讯作者：
Hureaux J
影响因子：
9.3
作者：
Skougaard, Kristin;Nielsen, Dorte;Hendel, Helle Westergren
通讯作者：
Hendel, Helle Westergren
影响因子：
3.8
作者：
Deasy, JO;Blanco, AI;Clark, VH
通讯作者：
Clark, VH
DOI：
10.1093/jnci/93.24.1879
发表时间：
2001-12-19
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
Matthews, NE;Adams, MA;Graham, CH
通讯作者：
Graham, CH